Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab effectiveness in severe COVID-19
IRCT20150303021315N22Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of adalimumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Mortality rate. Started Jul 2020; status: completed.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20150303021315N22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N22.